Researcher
Els Van Valckenborgh
- Keywords:Medicine
Affiliations
- Faculty of Medicine and Pharmacy (Faculty)
Member
From22 Jun 2017 → 7 Sep 2017 - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2014 → 30 Sep 2018 - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2014 → 30 Sep 2017 - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2014 → 30 Sep 2017 - Immunology and Microbiology (Department)
Member
From1 Feb 2012 → 31 Dec 2013 - Hematology (Research group)
Member
From1 Oct 2000 → 31 Dec 2014 - Immunology and Microbiology (Department)
Member
From1 Aug 2000 → 31 Dec 2013
Projects
1 - 5 of 5
- A study to target tumor-associated macrophages in multiple myeloma.From1 Jan 2016 → 31 Dec 2016Funding: FWO research grant KAN
- Drug resistance in multiple myeloma: study of extrinsic mechanisms governed by the bone marrow microenvironmentFrom1 Jan 2014 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
- Study of resistance mechanisms in multiple myelomaFrom1 Jan 2013 → 31 Dec 2013Funding: FWO research grant KAN
- The interest of aldehyde dehydrogenase positive cells in the evolution of multiple myelomaFrom1 Jan 2011 → 31 Dec 2011Funding: FWO research grant KAN
- Identification and characterisation of the cancer stem cell in multiple myelomaFrom1 Jan 2009 → 31 Dec 2009Funding: FWO research grant KAN
Publications
11 - 20 of 75
- The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells(2015)
Authors: Jinheng Wang, Kim De Veirman, Nathan De Beule, Ken Maes, Elke De Bruyne, E Van Valckenborgh, Karin Vanderkerken, Eline Menu
Pages: 43992-44004 - Novel strategies to target the ubiquitin proteasome system in multiple myeloma(2015)
Authors: Susanne Lub, Ken Maes, Eline Menu, Elke De Bruyne, Karin Vanderkerken, E Van Valckenborgh
Pages: 6521-6537 - Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment(2015)
Authors: Charlotte Fristedt Duvefelt, Susanne Lub, Prasoon Agarwal, Linda Arngården, Anna Hammarberg, E Van Valckenborgh, Helena Jernberg-Wiklund
Pages: 20621-20635 - Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro (vol 12, pg 1763, 2013)(2015)
Authors: Jinsong Hu, E Van Valckenborgh, Dehui Xu, Song Xu, Benjamin Van Camp, Damian R Handisides, Charles P. Hart
Pages: 1762-1762 - Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells(2015)
Authors: Susanne Lub, Ivan Bautmans, Babatunde O Oyajobi, Miguel Lemaire, E Van Valckenborgh
Pages: 10532-10547 - In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma(2015)
Authors: Ken Maes, Eva De Smedt, Alboukadel Kassambara, Dirk Hose, Anja Seckinger, E Van Valckenborgh, Eline Menu, Bernard Klein, Karin Vanderkerken, Jérôme Moreaux, et al.
Pages: 3319-3334 - Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche(2015)
Authors: Michelle A Lawson, Michelle M McDonald, Natasa Kovacic, Weng Hua Khoo, Rachael L Terry, Jenny Down, Warren Kaplan, Julia Paton-Hough, Clair Fellows, Jessica A Pettitt, et al.
- In vivo treatment withepigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma(2014)
Authors: Alboukadel Kassambara, D. Hose, Anja Seckinger, Els Van Valckenborgh, Bernard Klein, Jérôme Moreaux
Pages: 3319-3334 - Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.(2014)
Authors: E Van Valckenborgh, Qods Lahmar
Pages: 1-11 - The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma(2014)
Authors: Alboukadel Kassambara, D. Hose, Anja Seckinger, E Van Valckenborgh, Bernard Klein, Jérôme Moreaux
Pages: 3375